These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25387568)

  • 1. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
    Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
    Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
    Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
    Yuan YQ; Zhang YX; Liu ZH; Qin CP; Sheng ZZ; Xu T; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):571-6. PubMed ID: 26284387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.
    Yuan Y; Sheng Z; Liu Z; Zhang X; Xiao Y; Xie J; Zhang Y; Xu T
    J Cancer; 2020; 11(13):3762-3770. PubMed ID: 32328181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
    Xiao YB; Xie J; Zhang GX; Li J; Hao YC; Zhang XW; Liu ZH; Xu T; Wang XF
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):195-9. PubMed ID: 22474980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines.
    Shao L; Cui Y; Li H; Liu Y; Zhao H; Wang Y; Zhang Y; Ng KM; Han W; Ma D; Tao Q
    Clin Cancer Res; 2007 Oct; 13(19):5756-62. PubMed ID: 17908965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research advances in CKLF-like MARVEL transmembrane domain containing member 5].
    Yuan YQ; Xiao YB; Liu ZH; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):625-8. PubMed ID: 23286412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.
    Zhang H; Nan X; Li X; Chen Y; Zhang J; Sun L; Han W; Li T
    Biochem Biophys Res Commun; 2014 May; 447(2):304-10. PubMed ID: 24721428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
    Xu T; Li J; Xiao YB; Liu ZH; Li Q; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 42(4):386-90. PubMed ID: 20721248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
    Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
    J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer.
    Li P; Liu K; Li L; Yang M; Gao W; Feng J; Lv Y; Qu X; Kong B
    Int J Gynecol Cancer; 2011 Oct; 21(7):1248-55. PubMed ID: 21841490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia.
    Niu J; Li H; Zhang Y; Li J; Xie M; Li L; Qin X; Qin Y; Guo X; Jiang Q; Liu Y; Chen S; Huang X; Han W; Ruan G
    Leuk Res; 2011 Jun; 35(6):771-6. PubMed ID: 21168207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities.
    Xie J; Yuan Y; Liu Z; Xiao Y; Zhang X; Qin C; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2014 Apr; 16(4):402-9. PubMed ID: 23907292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMTM5-v1 induces apoptosis in cervical carcinoma cells.
    Shao L; Guo X; Plate M; Li T; Wang Y; Ma D; Han W
    Biochem Biophys Res Commun; 2009 Feb; 379(4):866-71. PubMed ID: 19124004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bax-interacting factor-1 inhibits cell proliferation and promotes apoptosis in prostate cancer cells.
    Xu L; Wang Z; He SY; Zhang SF; Luo HJ; Zhou K; Li XF; Qiu SP; Cao KY
    Oncol Rep; 2016 Dec; 36(6):3513-3521. PubMed ID: 27748942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis.
    Cai B; Xiao Y; Li Y; Zheng S
    Oncol Lett; 2017 Aug; 14(2):1536-1542. PubMed ID: 28789377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
    Shen P; Sun J; Xu G; Zhang L; Yang Z; Xia S; Wang Y; Liu Y; Shi G
    Prostate; 2014 Jun; 74(9):946-58. PubMed ID: 24737412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma.
    Yu C; Wu G; Dang N; Zhang W; Zhang R; Yan W; Zhao Y; Gao L; Wang Y; Beckwith N; Yuan J; Yao L
    Cancer Biol Ther; 2011 Aug; 12(4):304-13. PubMed ID: 21623166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association of
    Liu TF; Lin T; Ren LH; Li GP; Peng JJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):856-862. PubMed ID: 33047719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.